Quo vadis, SPC?

Insights from expert Dr. Christopher Brückner

SPC News

Insights from expert Dr. Christopher Brückner


Our speaker, one of the leading SPC experts in Europe, give answers to questions around SPC referrals to the ECJ.  

1. What do you expect from the pending referral in the case of QH/Royalty Pharma (C 650/17) where the ECJ has to deal with individualised embodiment?
 

Contact

Jean-Claude Alexandre Ho, LL.M.
Lawyer, Conference Manager

+49 6221 500-675
jc.alexandreho@forum-institut.de

Contact

2. What can one expect from the pending referral in the case of Sandoz v Seale (C-114/18) where the ECJ was asked about common general knowledge?

3. What do you make of the pending referral in the Santen v INPI case (C-673/18) where the ECJ was asked again on the interpretation of „different application“ as in The Neurim case?

4. What can be expected from the pending ECJ referral Eli Lilly (C-239/19) with regards to third party market authorisation?

5. What do you think how the ECJ will decide in the pending referral Novartis (C-354/19) concerning further SPCs to a new indication?